Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
about
Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.REDESIGN: RDF-based Differential Signaling Framework for Precision Medicine Analytics.Microglia/Astrocytes-Glioblastoma Crosstalk: Crucial Molecular Mechanisms and Microenvironmental Factors
P2860
Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Durable response of glioblasto ...... nib, metformin and niacinamide
@en
Durable response of glioblasto ...... ib, metformin and niacinamide.
@nl
type
label
Durable response of glioblasto ...... nib, metformin and niacinamide
@en
Durable response of glioblasto ...... ib, metformin and niacinamide.
@nl
prefLabel
Durable response of glioblasto ...... nib, metformin and niacinamide
@en
Durable response of glioblasto ...... ib, metformin and niacinamide.
@nl
P2093
P2860
P356
P1433
P1476
Durable response of glioblasto ...... nib, metformin and niacinamide
@en
P2093
Angel Blanco
Arthur L Day
Jamie Buryanek
Mary F McGuire
Robert E Brown
Sigmund H Hsu
P2860
P304
P356
10.18632/ONCOSCIENCE.311
P577
2016-06-11T00:00:00Z